Make your money go further for just 25p per day


Mega-Trends: A troubling 2021 opens opportunities for recovery


Mega trends

Mega-Trends Investor's Champion logo
  • The Mega-Trends portfolio ended 2021 down 4%
  • The portfolio remains on the hunt for exciting innovation which is not yet being recognised by the market 

Without a repeat of star stock Tesla’s (US: TSLA) 2020 portfolio contribution (a 12.5-fold return), the Investor’s Champion Mega-Trends Portfolio struggled to maintain its pace of growth in 2021. After a decent, market-beating start to the year, momentum faltered in March as the tide turned on the high-growth, high-risk sections of the stock market. The portfolio closed the year down 7.3%.

But it’s not all bad news. The original £40,000 investment we made in 20 stocks…

Continue reading our content…

Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • Unlimited access to our market-beating portfolios
  • In-depth coverage of many of the world’s great companies
  • Unique insights from our top research team
Register FREE for access to limited content.
  • Company and markets insights
  • Sponsored content
  • Podcasts

Previous article Next article


Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.



Become a champion investor for just £90 a year. Benefit from our high performing portfolios:


More on Alphabet

Episode 12 of the Investor’s Champion Podcast

07/04/2024 · Podcasts

In this week's episode of the Investor’s Champion Podcast Chris and Lee run key news affecting…

Ultimate Stocks: an unloved gets a lift

09/02/2024 · Portfolio

Earnings updates covered here from members of our Ultimate Stocks portfolio include encouraging noises from an…

More on CRISPR Therapeutics

Mega-Trends: next big thing is a step closer

27/11/2023 · Portfolio

A technology which could have an even bigger impact upon the world than AI has just…

An immense opportunity

30/08/2022 · Portfolio

CRISPR Therapeutics’ therapy for sickle cell disease could be available next year; this is incredibly exciting…

More on IDEXX Laboratories

Ultimate Stocks: July ‘22 portfolio update

19/07/2022 · Portfolio

Our Ultimate Stocks portfolio delivers relative outperformance over a very difficult period for stock markets. Our…

Mega-Trends: A troubling 2021 opens opportunities for recovery

11/02/2022 · Portfolio

Sign-up to our free email updates